NeuroVive Pharmaceutical AB Interim Report January - March 2019
First subjects enrolled in the KL1333 studyImportant events January-March 2019 · NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study. · NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds. · NeuroVive receives SEK 28.2 Million in a directed new share issue. · NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds. Important events after the reporting period · The Supreme Court had delivered its ruling concerning arbitration between NeuroVive and CicloMulsion AG. NeuroVive